Cited by 405TGF-β signaling in diseasesMechanisms of cancer metastasisCancer Cells and Metastasis

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects

Open access

Yang, Yu-an, Dukhanina, Oksana, Tang, Binwu, Mamura, Mizuko, Letterio, John J., MacGregor, Jennifer, Patel, Sejal C., Khozin, Shahram, Liu, Zi-yao, Green, Jeffrey, Anver, Miriam R., Merlino, Glenn, Wakefield, Lalage M.·2002·Journal of Clinical Investigation

DOI 10.1172/jci200215333PMC PMC151015

Open this paper in CoChat — free account Open PDF

Abstract

TGF-βs play diverse and complex roles in many biological processes. In tumorigenesis, they can function either as tumor suppressors or as pro-oncogenic factors, depending on the stage of the disease. We have developed transgenic mice expressing a TGF-β antagonist of the soluble type II TGF-β receptor:Fc fusion protein class, under the regulation of the mammary-selective MMTV-LTR promoter/enhancer. Biologically significant levels of antagonist were detectable in the serum and most tissues of this mouse line. The mice were resistant to the development of metastases at multiple organ sites when compared with wild-type controls, both in a tail vein metastasis assay using isogenic melanoma cells and in crosses with the MMTV-neu transgenic mouse model of metastatic breast cancer. Importantly, metastasis from endogenous mammary tumors was suppressed without any enhancement of primary tumorigenesis. Furthermore, aged transgenic mice did not exhibit the severe pathology characteristic of TGF-β null mice, despite lifetime exposure to the antagonist. The data suggest that in vivo the antagonist may selectively neutralize the undesirable TGF-β associated with metastasis, while sparing the regulatory roles of TGF-βs in normal tissues. Thus this soluble TGF-β antagonist has potential for long-term clinical use in the prevention of metastasis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1172/jci200215333

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Manipulating the mouse embryo: A laboratory manual
Hogan, B. L. M., Costantini, F. D., & Lacy, E. (1986) · Cited by 4,460
Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease
Shull, M. M., Ormsby, I., Kier, A. B., Pawlowski, S., Diebold, R. J., Yin, M., Allen, R., Sidman, C., Proetzel, G., Calvin, D., et al. (1992) · Nature · doi:10.1038/359693a0 · Cited by 2,985
TGFβ Signaling in Growth Control, Cancer, and Heritable Disorders
Massagué, J., Blain, S. W., & Lo, R. S. (2000) · Cell · doi:10.1016/s0092-8674(00)00121-5 · Cited by 2,391
TGF-β Signaling in Tumor Suppression and Cancer Progression
Derynck, R., Akhurst, R. J., & Balmain, A. (2001) · Nature Genetics · doi:10.1038/ng1001-117 · Cited by 2,275
Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death.
Kulkarni, A. B., Huh, C. G., Becker, D., Geiser, A., Lyght, M., Flanders, K. C., Roberts, A. B., Sporn, M. B., Ward, J. M., & Karlsson, S. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.770 · Cited by 1,967
Peptide Growth Factors and Their Receptors
Arai, K., Battey, J. F., Sporn, M. B., & Roberts, A. B. (1991) · Medical Entomology and Zoology · Cited by 1,225
Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease.
Guy, C. T., Webster, M. A., Schaller, M. D., Parsons, T. J., Cardiff, R. D., & Muller, W. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.22.10578 · Cited by 1,193
Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1
Border, W. A., Okuda, S., Languino, L. R., Sporn, M. B., & Ruoslahti, E. I. (1990) · Nature · doi:10.1038/346371a0 · Cited by 984
Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease
Border, W. A., Noble, N. A., Yamamoto, T., Harper, J. R., Yamaguchi, Y., Pierschbacher, M. D., & Ruoslahti, E. I. (1992) · Nature · doi:10.1038/360361a0 · Cited by 972
Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice
Wang, T. C., Cardiff, R. D., Zukerberg, L. R., Lees, E. M., Arnold, A., & Schmidt, E. V. (1994) · Nature · doi:10.1038/369669a0 · Cited by 964

Flagged first, then by citations

Show all 50 references

Research works printed but not linked: 4

Gold, 1999, Crit Rev Oncog, 10, 303
Engle, 1999, Cancer Res, 59, 3379
Bottinger, 1997, Cancer Res, 57, 5564
Dalal, 1993, Am J Pathol, 143, 381

Sorted by citations

Items 101–200 of 405

Effect of Smad7 Expression on Metastasis of Mouse Mammary Carcinoma JygMC(A) Cells
Azuma, H., Ehata, S., Miyazaki, H., Watabe, T., Maruyama, O., Imamura, T., Sakamoto, T., Kiyama, S., Kiyama, Y., Ubai, T., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji399 · Cited by 115
Keloids demonstrate high-level epidermal expression of vascular endothelial growth factor
Gira, A. K., Brown, L. F., Washington, C. V., Cohen, C., & Arbiser, J. L. (2004) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2003.11.061 · Cited by 109
A Novel Lung Cancer Signature Mediates Metastatic Bone Colonization by a Dual Mechanism
Vicent, S., Luis-Ravelo, D., Antón, I., García‐Tuñón, I., Borrás‐Cuesta, F., Dotor, J., Rivas, J. D. L., & Lecanda, F. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6493 · Cited by 113
Idiopathic pulmonary fibrosis: new insights into pathogenesis
Noble, P. W., & Homer, R. (2004) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2004.04.003 · Cited by 109
Antitransforming growth factor-β therapy in fibrosis: recent progress and implications for systemic sclerosis
Varga, J., & Pasche, B. (2008) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32830e48e8 · Cited by 107
Targeting TGF-β in prostate cancer: therapeutic possibilities during tumor progression
Jones, E., Pu, H., & Kyprianou, N. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220802705696 · Cited by 109
TGF-β antagonists: Why suppress a tumor suppressor?
Akhurst, R. J. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215970 · Cited by 108
Drug development against metastasis-related genes and their pathways: A rationale for cancer therapy
Iiizumi, M., Liu, W., Pai, S. K., Furuta, E., & Watabe, K. (2008) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.07.002 · Cited by 104
Tumor-promoting functions of transforming growth factor-β in progression of cancer
Miyazono, K., Ehata, S., & Koinuma, D. (2011) · Upsala Journal of Medical Sciences · doi:10.3109/03009734.2011.638729 · Cited by 106
Inhibition of TGFβ signaling in cancer therapy
Arteaga, C. L. (2005) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2005.12.009 · Cited by 105
Targeting the Transforming Growth Factor-β Signaling in Cancer Therapy
Sheen, Y. Y., Kim, M. J., Park, S. A., Park, S.-Y., & Nam, J. (2013) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2013.072 · Cited by 106
Cancer Associated Fibroblasts: Naughty Neighbors That Drive Ovarian Cancer Progression
Dasari, S., Fang, Y., & Mitra, A. K. (2018) · Cancers · doi:10.3390/cancers10110406 · Cited by 102
α2HS-glycoprotein, an Antagonist of Transforming Growth Factor β In vivo , Inhibits Intestinal Tumor Progression
Swallow, C. J., Partridge, E. A., Macmillan, J. C., Tajirian, T., Guglielmo, G. M. D., Hay, K., Szweras, M., Jahnen‐Dechent, W., Wrana, J. L., Redston, M. S., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1117 · Cited by 102
The G protein‐coupled receptor kinase‐2 is a TGFβ‐inducible antagonist of TGFβ signal transduction
Ho, J., Cocolakis, E., Dumas, V. M., Posner, B. I., Laporte, S. A., & Lebrun, J. J. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600794 · Cited by 98
The role of TGF-β in bone metastasis: novel therapeutic perspectives
Buijs, J. T., Stayrook, K. R., & Guise, T. A. (2012) · BoneKEy Reports · doi:10.1038/bonekey.2012.96 · Cited by 99
Orchestrating the Tumor Microenvironment to Improve Survival for Patients With Pancreatic Cancer
Whatcott, C. J., Han, H., & Hoff, D. D. V. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000140 · Cited by 96
Squamous cell carcinoma and mammary abscess formation through squamous metaplasia inSmad4/Dpc4conditional knockout mice
Li, W.-M., Qiao, W., Chen, L., Xu, X., Yang, X. Y., Li, D., Li, C., Brodie, S. G., Meguid, M. M., Hennighausen, L. G., et al. (2003) · Development · doi:10.1242/dev.00820 · Cited by 99
TGFβ restores hematopoietic homeostasis after myelosuppressive chemotherapy
Brenet, F. A., Kermani, P., Spektor, R., Rafii, S., & Scandura, J. M. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20121610 · Cited by 96
Molecular interactions between breast cancer cells and the bone microenvironment drive skeletal metastases
Siclari, V. A., Guise, T. A., & Chirgwin, J. M. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9023-1 · Cited by 95
X-linked Inhibitor of Apoptosis (XIAP) Inhibits c-Jun N-terminal Kinase 1 (JNK1) Activation by Transforming Growth Factor β1 (TGF-β1) through Ubiquitin-mediated Proteosomal Degradation of the TGF-β1-activated Kinase 1 (TAK1)
Kaur, S., Wang, F., Manickam, V., & Arsura, M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505671200 · Cited by 96
Anti-Transforming Growth Factor ß Antibody Treatment Rescues Bone Loss and Prevents Breast Cancer Metastasis to Bone
Biswas, S., Nyman, J. S., Alvarez, J., Chakrabarti, A., Ayres, A., Sterling, J. A. R., Edwards, J., Rana, T., Johnson, R. W., Perrien, D. S., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027090 · Cited by 93
Targeting the transforming growth factor-β signalling pathway in metastatic cancer
Korpal, M., & Kang, Y. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.040 · Cited by 96
Collaborative activities of macrophage-stimulating protein and transforming growth factor-β1 in induction of epithelial to mesenchymal transition: roles of the RON receptor tyrosine kinase
Wang, D., Shen, Q., Chen, Y., & Wang, M. (2004) · Oncogene · doi:10.1038/sj.onc.1207282 · Cited by 91
Inhibition of Breast Cancer Metastases by a Novel Inhibitor of TGFβ Receptor 1
Fang, Y., Chen, Y., Yu, L., Zheng, C., Ya, Q., Li, Z., Yang, Z., Zhang, Y., Shi, T., Luo, J., et al. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs485 · Cited by 91
Transforming growth factor-β pathway: Role in pancreas development and pancreatic disease
Rane, S. G., Lee, J., & LIN, H. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.09.003 · Cited by 91
Inhibiting TGF-β signaling in hepatocellular carcinoma
Giannelli, G., Mazzocca, A., Fransvea, E., Lahn, M., & Antonaci, S. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.11.004 · Cited by 86
Bone Sialoprotein Mediates the Tumor Cell–Targeted Prometastatic Activity of Transforming Growth Factor β in a Mouse Model of Breast Cancer
Nam, J., Suchar, A. M., Kang, M., Stuelten, C. H., Tang, B., Michalowska, A. M., Fisher, L. W., Fedarko, N. S., Jain, A., Pinkas, J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0068 · Cited by 86
Self-citation
Outgrowth of Drug-Resistant Carcinomas Expressing Markers of Tumor Aggression after Long-term TβRI/II Kinase Inhibition with LY2109761
Connolly, E. C., Saunier, E. F., Quigley, D., Luu, M. T., De Sapio, A., Hann, B., Yingling, J. M., & Akhurst, R. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2941 · Cited by 82
Perspective: The right trials
Steeg, P. S. (2012) · Nature · doi:10.1038/485s58a · Cited by 82
TGF-beta signaling in cancer radiotherapy
Wang, J., Xu, Z., Wang, Z., Du, G., & Lun, L. (2021) · Cytokine · doi:10.1016/j.cyto.2021.155709 · Cited by 87
The promise of genetically engineered mice for cancer prevention studies
Green, J. E., & Hudson, T. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1565 · Cited by 82
Self-citation
Blockade of TGF‐β enhances tumor vaccine efficacy mediated by CD8+ T cells
Takaku, S., Terabe, M., Ambrosino, E., Peng, J., Lonning, S. M., McPherson, J. M., & Berzofsky, J. A. (2009) · International Journal of Cancer · doi:10.1002/ijc.24961 · Cited by 83
TGF-β inhibitors for the treatment of cancer
Lahn, M. M. F., Kloeker, S., & Berry, B. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.6.629 · Cited by 84
Transforming Growth Factor β (TGF-β)-Smad Target Gene Protein Tyrosine Phosphatase Receptor Type Kappa Is Required for TGF-β Function
Wang, S. E., Wu, F. Y., Shin, I., Qu, S., & Arteaga, C. L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.11.4703-4715.2005 · Cited by 83
Role of Transforming Growth Factor-β In Cancer Progression
Galliher, A. J., Neil, J. R., & Schiemann, W. P. (2006) · Future Oncology · doi:10.2217/14796694.2.6.743 · Cited by 80
Retraction: GQ5 Hinders Renal Fibrosis in Obstructive Nephropathy by Selectively Inhibiting TGF-β–Induced Smad3 Phosphorylation
Ai, J., Nie, J., He, J., Guo, Q., Li, M., Lei, Y., Liu, Y., Zhou, Z., Zhu, F., Liang, M., et al. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014040363 · Cited by 78
Retracted
Tumor-Stromal Interactions in Pancreatic Cancer
Whatcott, C. J., Han, H., Posner, R. G., & Hoff, D. D. V. (2012) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v18.i1-2.80 · Cited by 80
Interaction of Tumor with Its Micro-environment: A Mathematical Model
Kim, Y., & Friedman, A. (2009) · Bulletin of Mathematical Biology · doi:10.1007/s11538-009-9481-z · Cited by 75
Convergence of p53 and TGF-beta signaling networks
Dupont, S., Zacchigna, L., Adorno, M., Soligo, S., Volpin, D., Piccolo, S., & Cordenonsi, M. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.06.008 · Cited by 76
TGF-β in the Bone Microenvironment: Role in Breast Cancer Metastases
Buijs, J. T., Stayrook, K. R., & Guise, T. A. (2011) · Cancer Microenvironment · doi:10.1007/s12307-011-0075-6 · Cited by 76
Mechanisms in Epithelial Plasticity and Metastasis: Insights from 3D Cultures and Expression Profiling
Jechlinger, M., Grünert, S., & Beug, H. (2002) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1024090116451 · Cited by 78
Targeting key steps in metastatic tumour progression
Eccles, S. A. (2005) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2004.12.001 · Cited by 73
Role of TGF-β in breast cancer bone metastases
Chiechi, A., Waning, D. L., Stayrook, K. R., Buijs, J. T., Guise, T. A., & Mohammad, K. S. (2013) · Advances in Bioscience and Biotechnology · doi:10.4236/abb.2013.410a4003 · Cited by 76
Gr‐1+CD11b+ cells are responsible for tumor promoting effect of TGF‐β in breast cancer progression
Li, Z., Pang, Y., Gara, S. K., Achyut, B. R., Heger, C. D., Goldsmith, P. K., Lonning, S. M., & Yang, H. H. (2012) · International Journal of Cancer · doi:10.1002/ijc.27572 · Cited by 75
Diffuse-Type Gastric Carcinoma: Progression, Angiogenesis, and Transforming Growth Factor β Signaling
Komuro, A., Yashiro, M., Iwata, C., Morishita, Y., Johansson, E., Matsumoto, Y., Watanabe, A., Aburatani, H., Miyoshi, H., Kiyono, K., et al. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp058 · Cited by 73
Activin receptor‐like kinase5 inhibition suppresses mouse melanoma by ubiquitin degradation of Smad4, thereby derepressing eomesodermin in cytotoxic T lymphocytes
Yoon, J., Jung, S. M., Park, S. H., Kato, M., Yamashita, T., Lee, I., Sudo, K., Nakae, S., Han, J. S., Kim, O., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302524 · Cited by 73
Self-citation
TGF-β/Smad Signalling in Neurogenesis: Implications for Neuropsychiatric Diseases
Hiew, L.-F., Poon, C.-H., You, H.-Z., & Lim, L.-W. (2021) · Cells · doi:10.3390/cells10061382 · Cited by 71
Functional Proteomics Approach to Investigate the Biological Activities of cDNAs Implicated in Breast Cancer
Witt, A. E., Hines, L. M., Collins, N. L., Hu, Y., Gunawardane, R. N., Moreira, D., Raphael, J., Jepson, D., Koundinya, M., Rolfs, A., et al. (2006) · Journal of Proteome Research · doi:10.1021/pr050395r · Cited by 71
Parallels in invasion and angiogenesis provide pivotal points for therapeutic intervention
Eccles, S. A. (2004) · The International Journal of Developmental Biology · doi:10.1387/ijdb.041820se · Cited by 71
Targeting transforming growth factor-β signaling
Pennison, M. J., & Pasche, B. (2007) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3282f0ad0e · Cited by 71
Designing proteins for bone targeting
Gittens, S. A., BANSAL, G., Zernicke, R. F., & Uludağ, H. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.12.015 · Cited by 68
Transforming growth factor-beta and its implication in the malignancy of gliomas
Roy, L.-O., Poirier, M.-B., & Fortin, D. (2014) · Targeted Oncology · doi:10.1007/s11523-014-0308-y · Cited by 69
Soluble Type II Transforming Growth Factor-β Receptor Inhibits Established Murine Malignant Mesothelioma Tumor Growth by Augmenting Host Antitumor Immunity
Suzuki, E., Kapoor, V., Cheung, H.-K., Ling, L. E., DeLong, P. A., Kaiser, L. R., & Albelda, S. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0611 · Cited by 65
Activin signaling is an essential component of the TGF-β induced pro-metastatic phenotype in colorectal cancer
Staudacher, J. J., Bauer, J. I., Jana, A., Tian, J., Carroll, T. P., Mancinelli, G. E., Özden, Ö., Krett, N. L., Guzman, G., Kerr, D. J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-05907-8 · Cited by 65
Interaction with Smad4 Is Indispensable for Suppression of BMP Signaling by c-Ski
Takeda, M., Mizuide, M., Oka, M., Watabe, T., Inoue, H., Suzuki, H., Fujita, T., Imamura, T., Miyazono, K., & Miyazawa, K. (2003) · Molecular Biology of the Cell · doi:10.1091/mbc.e03-07-0478 · Cited by 65
Modeling Metastatic Breast Cancer in Mice
Jonkers, J., & Derksen, P. W. B. (2007) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-007-9050-8 · Cited by 64
Targeting TGF beta signaling for cancer therapy
Iyer, S., Wang, Z., Akhtari, M., Zhao, W., & Seth, P. K. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.3.1566 · Cited by 65
Signaling through ShcA Is Required for Transforming Growth Factor β- and Neu/ErbB-2-Induced Breast Cancer Cell Motility and Invasion
Northey, J. J., Chmielecki, J., Ngan, E., Russo, C., Annis, M., Muller, W., & Siegel, P. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01734-07 · Cited by 73
T he R ole of TGF-β in E pithelial M alignancy and its R elevance to the P athogenesis of O ral C ancer (P art II)
Prime, S. S., Davies, M., Pring, M., & Paterson, I. C. (2004) · Critical Reviews in Oral Biology & Medicine · doi:10.1177/154411130401500603 · Cited by 63
Transforming growth factor-beta facilitates breast carcinoma metastasis by promoting tumor cell survival
Yu, Q., & Stamenkovic, I. (2004) · Clinical & Experimental Metastasis · doi:10.1023/b:clin.0000037705.25256.d3 · Cited by 62
TGF-β in cancer and as a therapeutic target
Pinkas, J., & Teicher, B. A. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.03.004 · Cited by 61
Antitumor activity of TGF-beta inhibitor is dependent on the microenvironment.
Medicherla, S., Li, L., Jing, Y., Kapoun, A. M., Gaspar, N. J., Liu, Y.-W., Mangadu, R., O’Young, G., Protter, A. A., Schreiner, G. F., et al. (2007) · PubMed · Cited by 61
Transforming growth factor-β1 upregulates the expression of CXC chemokine receptor 4 (CXCR4) in human breast cancer MCF-7 cells
Zhao, X., Huang, Y., Huang, Y., Lei, P., Peng, J., Wu, S., Wang, M., Li, W., Zhu, H., & Shen, G. (2010) · Acta Pharmacologica Sinica · doi:10.1038/aps.2009.204 · Cited by 61
Idiopathic Pulmonary Fibrosis
Kaminski, N., Belperio, J. A., Bitterman, P. B., Chen, L., Chensue, S. W., Choi, A. M. K., Đačić, S., Dauber, J. H., du Bois, R. M., Enghild, J. J., et al. (2003) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2003-0159su · Cited by 62
TGF-β S ignal T ransduction in O ro - facial H ealth and N on - malignant D isease (P art I)
Prime, S. S., Pring, M., Davies, M., & Paterson, I. C. (2004) · Critical Reviews in Oral Biology & Medicine · doi:10.1177/154411130401500602 · Cited by 61
Personalized Dendritic Cell-Based Tumor Immunotherapy
Janikashvili, N., Larmonier, N., & Katsanis, E. (2009) · Immunotherapy · doi:10.2217/imt.09.78 · Cited by 62
Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-β signaling in ErbB2/Neu-induced tumors from transgenic mice
Landis, M. D., Seachrist, D. D., Montanez-Wiscovich, M. E., Danielpour, D., & Keri, R. A. (2005) · Oncogene · doi:10.1038/sj.onc.1208712 · Cited by 58
TGF-β signaling pathway: Therapeutic targeting and potential for anti-cancer immunity
Ali, S., Rehman, M. U., Yatoo, A. M., Arafah, A. M., Khan, A., Rashid, S., Majid, S., Ali, A., & Ali, M. N. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175678 · Cited by 60
Inhibition of TGF-β modulates macrophages and vessel maturation in parallel to a lowering of interstitial fluid pressure in experimental carcinoma
Salnikov, A. V., Roswall, P., Sundberg, C., Gardner, H., Heldin, N., & Rubin, K. (2005) · Laboratory Investigation · doi:10.1038/labinvest.3700252 · Cited by 58
TGF-² Signaling Pathway in Lung Adenocarcinoma Invasion
Toonkel, R. L., Borczuk, A., & Powell, C. A. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181c8cc0c · Cited by 58
Development of small molecule inhibitors targeting TGF-β ligand and receptor: Structures, mechanism, preclinical studies and clinical usage
Wang, H., Chen, M., Sang, X., You, X., Wang, Y., Paterson, I. C., Hong, W., & Yang, X. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112154 · Cited by 56
The TGFß pathway as a therapeutic target in cancer
Seoane, J. (2008) · Clinical & Translational Oncology · doi:10.1007/s12094-008-0148-2 · Cited by 58
An novel inhibitor of TGF-β type I receptor, IN-1130, blocks breast cancer lung metastasis through inhibition of epithelial–mesenchymal transition
Park, C., Min, K. N., Son, J., Park, S.-Y., Nam, J., Kim, D., & Sheen, Y. Y. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.05.006 · Cited by 59
Erratum To: Activin receptor‐like kinase5 inhibition suppresses mouse melanoma by ubiquitin degradation of Smad4, thereby derepressing eomesodermin in cytotoxic T lymphocytes
Yoon, J., Jung, S. M., Park, S. H., Kato, M., Yamashita, T., Lee, I., Sudo, K., Nakae, S., Han, J. S., Kim, O., et al. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201470040 · Cited by 57
Self-citation
Role of TGF-β in cancer and the potential for therapy and prevention
Kaklamani, V., & Pasche, B. (2004) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.4.4.649 · Cited by 57
Breast cancer bone metastasis and current small therapeutics
Cicek, M., & Oursler, M. J. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9035-x · Cited by 55
MDSC and TGFβ Are Required for Facilitation of Tumor Growth in the Lungs of Mice Exposed to Carbon Nanotubes
Shvedova, A. A., Kisin, E. R., Yanamala, N. V. K., Tkach, A. V., Gutkin, D. W., Star, A., Shurin, G. V., Kagan, V. E., & Shurin, M. R. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2376 · Cited by 53
Targeting the Tumor Stroma as a Novel Therapeutic Approach for Prostate Cancer
Franco, O. E., & Hayward, S. W. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-397927-8.00009-9 · Cited by 54
Interference with TGF‐β1 and ‐β3 in tumor stroma lowers tumor interstitial fluid pressure independently of growth in experimental carcinoma
Lammerts, E., Roswall, P., Sundberg, C., Gotwals, P. J., Koteliansky, V., Reed, R. K., Heldin, N., & Rubin, K. (2002) · International Journal of Cancer · doi:10.1002/ijc.10722 · Cited by 55
Transmembrane Domain Targeting Peptide Antagonizing ErbB2/Neu Inhibits Breast Tumor Growth and Metastasis
Arpel, A., Sawma, P., Spenlé, C., Fritz, J., Meyer, L. A. T., Garnier, N., Velázquez-Quesada, I., Hussenet, T., Aci‐Sèche, S., Baumlin, N., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.07.044 · Cited by 52
Minimal Effects on Immune Parameters Following Chronic Anti-TGF-β Monoclonal Antibody Administration to Normal Mice
Ruzek, M. C., Hawes, M. L., Pratt, B. M., McPherson, J. M., Ledbetter, S., Richards, S. M., & Garman, R. D. (2003) · Immunopharmacology and Immunotoxicology · doi:10.1081/iph-120020473 · Cited by 52
Microarray identifies ADAM family members as key responders to TGF-β1 in alveolar epithelial cells
Keating, D., Sadlier, D. M., Patricelli, A., Smith, S. M., Walls, D., Egan, J. J., & Doran, P. (2006) · Respiratory Research · doi:10.1186/1465-9921-7-114 · Cited by 52
Structural determinants of heparin–transforming growth factor-β1 interactions and their effects on signaling
Lee, J. H., Wee, S., Gunaratne, J., Chua, R. J. E., Smith, R. A. A., Ling, L., Fernig, D. G., Swaminathan, K., Nurcombe, V., & Cool, S. M. (2015) · Glycobiology · doi:10.1093/glycob/cwv064 · Cited by 52
TGF‐β signaling in liver metastasis
Marvin, D. L., Heijboer, R., ten Dijke, P., & Ritsma, L. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.160 · Cited by 53
Enhanced tenascin-C expression and matrix deposition during Ras/TGF-β-induced progression of mammary tumor cells
Macho‐Maschler, S., Grünert, S., Danielopol, A., Beug, H., & Wirl, G. (2004) · Oncogene · doi:10.1038/sj.onc.1207403 · Cited by 51
Transformed epithelial cells and fibroblasts/myofibroblasts interaction in breast tumor: a mathematical model and experiments
Kim, Y., Wallace, J. A., Li, F., Ostrowski, M. C., & Friedman, A. (2009) · Journal of Mathematical Biology · doi:10.1007/s00285-009-0307-2 · Cited by 52
Efficient TGF-β/SMAD signaling in human melanoma cells associated with high c-SKI/SnoN expression
Javelaud, D., van Kempen, L. C. L. T., Alexaki, V. I., Scolan, E. L., Luo, K., & Mauviel, A. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-2 · Cited by 51
Desmoplasia and chemoresistance in pancreatic cancer
Whatcott, C. J., Posner, R. G., Hoff, D. D. V., & Han, H. (2012) · Europe PMC (PubMed Central) · Cited by 50
TGF-β-induced apoptosis in human thyrocytes is mediated by p27kip1 reduction and is overridden in neoplastic thyrocytes by NF-κB activation
Bravo, S. B., Pampín, S., Cameselle‐Teijeiro, J., Carneiro, C., Domı́nguez, F., Barreiro, F. J. J., & Álvarez, C. V. (2003) · Oncogene · doi:10.1038/sj.onc.1207029 · Cited by 50
Systemic Delivery of an Oncolytic Adenovirus Expressing Soluble Transforming Growth Factor- β Receptor II–Fc Fusion Protein Can Inhibit Breast Cancer Bone Metastasis in a Mouse Model
Hu, Z., Zhang, Z., Guise, T. A., & Seth, P. K. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.018 · Cited by 49
The not-so innocent bystander: the microenvironment as a therapeutic target in cancer
Erickson, A., & Barcellos‐Hoff, M. H. (2003) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.7.1.71 · Cited by 49
Transforming growth factor-β signaling in tumor initiation, progression and therapy in breast cancer: an update
Zu, X., Zhang, Q., Cao, R., Liu, J., Zhong, J., Wen, G., & Cao, D. (2011) · Cell and Tissue Research · doi:10.1007/s00441-011-1225-3 · Cited by 48
Pro‐metastasis function of TGFβ mediated by the smad pathway
Kang, Y. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20928 · Cited by 49
Enhancer Reprogramming within Pre-existing Topologically Associated Domains Promotes TGF-β-Induced EMT and Cancer Metastasis
Qiao, Y., Wang, Z., Tan, F., Chen, J., Lin, J., Yang, J., Li, H., Wang, X., Šali, A., Zhang, L., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.05.026 · Cited by 49
Tumor-suppressive and promoting function of transforming growth factor beta
Sun, L. (2004) · Frontiers in bioscience · doi:10.2741/1382 · Cited by 46
Seed, soil and secreted hormones: Potential interactions of breast cancer cells with their endocrine/paracrine microenvironment and implications for treatment with bisphosphonates
Wilson, C., Holen, I., & Coleman, R. E. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.02.007 · Cited by 46
Differential regulation of extracellular matrix protein expression in carcinoma-associated fibroblasts by TGF-β1 regulates cancer cell spreading but not adhesion
Bockstal, M. V., Lambein, K., Gele, M. V., Vlieghere, E. D., Limame, R., Braems, G., den Broecke, R. V., Cocquyt, V., Denys, H. G., Bracke, M., et al. (2014) · Oncoscience · doi:10.18632/oncoscience.87 · Cited by 48
Inhibition of TGFβ signaling and its implications in anticancer treatments.
Calone, I., & Souchelnytskyi, S. (2012) · PubMed · Cited by 46
Circulating transforming growth factor-β-1 and breast cancer prognosis: results from the Shanghai Breast Cancer Study
Grau, A. M., Wen, W., Ramroopsingh, D. S., Gao, Y., Zi, J., Cai, Q., Shu, X., & Zheng, W. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9845-8 · Cited by 45
Targeting the stromal microenvironment in chronic inflammation
FILER, A., PITZALIS, C., & BUCKLEY, C. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.03.007 · Cited by 45

Authors: Yang, Y.-A., Dukhanina, O., Tang, B., Mamura, M., Letterio, J. J., MacGregor, J., Patel, S. C., Khozin, S., Liu, Z.-Y., Green, J., Anver, M. R., Merlino, G., & Wakefield, L. M.
Affiliations: National Institutes of Health (US)
Frederick National Laboratory for Cancer Research (US)
Corresponding author: Wakefield, Lalage M.
ORCID: Mamura, Mizuko
Letterio, John J.
Green, Jeffrey
Anver, Miriam R.
Merlino, Glenn
Wakefield, Lalage M.
Venue: Journal of Clinical Investigation
Publisher: American Society for Clinical Investigation
Published: 2002-06-15
Volume: 109
Issue: 12
Pages: 1607-1615
ISSN: 0021-9738 (ISSN-L)
DOI: 10.1172/jci200215333
PMC: PMC151015
OpenAlex: W2118916648
Cited by: 404
References: 50
Citations by year: 2026: 1 · 2025: 4 · 2024: 1 · 2023: 4 · 2022: 3 · 2021: 8 · 2020: 9 · 2019: 5 · 2018: 5 · 2017: 6 · 2016: 8 · 2015: 9 · 2014: 17 · 2013: 19 · 2012: 30
FWCI: 12.90
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Investigation (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: U.S. Department of Health and Human Services
National Institutes of Health (n01co12400-79-0-22, NO1-CO12400)
National Cancer Institute (N01CO12400, N01-CO-012400, NO1‐CO‐12400)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords: TGF-beta antagonists, Fc fusion protein, metastasis prevention, melanoma metastasis, MMTV-neu transgenic mice, breast cancer, transgenic mice
MeSH terms: Receptor, Transforming Growth Factor-beta Type II, Animals, Female, Genetic Vectors, Humans, Immunoglobulin G, Immunoglobulin Fc Fragments, Liver Neoplasms, Mammary Tumor Virus, Mouse, Melanoma, Experimental, Mice, Transgenic, Neoplasm Metastasis, Recombinant Fusion Proteins, Solubility, Tumor Cells, Cultured, Mammary Neoplasms, Animal, Transforming Growth Factor beta, Protein Serine-Threonine Kinases, Receptors, Transforming Growth Factor beta, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks